Regulation of Glia-driven Neuroinflammation in Glaucoma
青光眼中神经胶质细胞驱动的神经炎症的调节
基本信息
- 批准号:9910408
- 负责人:
- 金额:$ 40万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-01 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:AmericanAnimal ModelAstrocytesAttentionAutoantibodiesAutopsyAxonBlindnessClinicalComparative StudyComplementDataDiseaseDrug TargetingEnsureGenetic TranscriptionGlaucomaHomeostasisHumanImageImmuneIndividualInflammationInflammation MediatorsInflammatoryInflammatory ResponseInjectionsInjuryMass Spectrum AnalysisMethodologyMethodsMicrogliaMicrospheresModelingMolecularMolecular AnalysisMouse StrainsMusNerve DegenerationNeurogliaNeuronal InjuryNeuronsOcular HypertensionOptic DiskOptic NerveOutcomeOutcome StudyPathway interactionsPatientsPharmaceutical PreparationsPhenotypePilot ProjectsPlayProcessProductionRegulationRetinaRoleSamplingSiteStructureT-LymphocyteTestingTimeTranscription CoactivatorTransgenic MiceTransgenic OrganismsVisionWorkadaptive immune responseanterior chamberbasecell typechemokinecytokinedesignevent cycleexperimental studyglial activationimmunogenicimmunoregulationinflammatory milieuneuroinflammationneuroprotectionneurotoxicneurotoxicitypreventresponsetreatment strategyviscoelasticity
项目摘要
PROJECT SUMMARY
Recent studies of clinical/postmortem and experimental samples have accumulated evidence that supports a
connection of inflammatory responses to neurodegeneration in glaucoma. Although inflammatory aspects of
glaucomatous neurodegeneration are attracting increasing attention, how neuroinflammation is regulated in
glaucoma, and how we can prevent neurodegenerative inflammation remain unknown. Here, we present
experimental data leading us to hypothesize that NF-κB plays a key role in activating the glia-driven
neuroinflammation in the glaucomatous retina and optic nerve, and that targeting this transcriptional activator
mechanism is a logical strategy to provide immunomodulation and avoid secondary injury processes. With respect
to intimate inter-relationship between astroglia and microglia in induction of the inflammatory/neurotoxic
phenotype, NF-κB, the key transcriptional activator of inflammatory mediators, should be critical for both glial
subtypes and their interaction in neuroinflammation in glaucoma. To test this hypothesis, we will comparatively
study glial subtype-targeted conditional transgenic lines (in which the NF-κB canonical pathway is inactivated by
drug-induced deletion of IκKβ in astroglia or microglia) and background controls with or without ocular
hypertension (induced by anterior chamber microbead/viscoelastic injections). We will longitudinally analyze glial
subtype-targeted transgenic effects on a diverse set of inflammatory outcomes at different sites of injury (retina,
optic nerve head, and optic nerve axons). The studied outcomes will include the glial inflammatory activation
phenotype and cell type-specific effects of glial subtype-targeted IκKβ deletion. Besides a preselected set of
molecules, freshly isolated samples of astroglia and microglia will be analyzed by quantitative mass spectrometry
to also gain high-throughput molecular information about transgenic effects on NF-κB-regulated inflammation
pathways, other transcriptional targets of NF-κB, and molecules relevant to glial neurosupport functions. Since glia
drive both innate and adaptive immune responses in glaucoma, additional analysis will include T-cell reactivity
and autoantibody production. To determine whether transgenic inhibition of glial NF-κB (and neuroinflammation)
protects neurons from immunogenic injury in mouse glaucoma, we will also analyze neuron structure (by RGC
and axon counts) and function (by PERG). We expect that this project, complementing the astroglia- or microglia-
targeted transgenic lines with molecular analysis of astroglia-specific and microglia-specific responses (in isolated
cell type-specific samples) will allow us to determine the role of NF-κB in individual contribution and inter-
relationship of astroglia and microglia in neuroinflammation (in the retina, optic nerve head, and axons),
characterize specific molecular components, and value glial NF-κB as a treatment target to restore immune
homeostasis and provide neuroprotection through immunomodulation in glaucoma.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gulgun TEZEL其他文献
Gulgun TEZEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gulgun TEZEL', 18)}}的其他基金
Oxidative Stress in Neurodegeneration & Neuroprotection in Glaucoma
神经退行性变中的氧化应激
- 批准号:
9042368 - 财政年份:2015
- 资助金额:
$ 40万 - 项目类别:
Proteomic Analysis of Retinal Ganglion Cell Death in Glaucoma
青光眼视网膜神经节细胞死亡的蛋白质组学分析
- 批准号:
7373784 - 财政年份:2007
- 资助金额:
$ 40万 - 项目类别:
Proteomic Analysis of Retinal Ganglion Cell Death in Glaucoma
青光眼视网膜神经节细胞死亡的蛋白质组学分析
- 批准号:
7531028 - 财政年份:2007
- 资助金额:
$ 40万 - 项目类别:
Proteomic Analysis of Retinal Ganglion Cell Death in Glaucoma
青光眼视网膜神经节细胞死亡的蛋白质组学分析
- 批准号:
7741650 - 财政年份:2007
- 资助金额:
$ 40万 - 项目类别:
TNF-alpha in cell death & neuroprotection in glaucoma
TNF-α在细胞死亡中的作用
- 批准号:
7100119 - 财政年份:2003
- 资助金额:
$ 40万 - 项目类别:
TNF-alpha in cell death & neuroprotection in glaucoma
TNF-α在细胞死亡中的作用
- 批准号:
6616471 - 财政年份:2003
- 资助金额:
$ 40万 - 项目类别:
TNF-alpha in Cell Death & Neuroprotection in Glaucoma
TNF-α 与细胞死亡
- 批准号:
7882346 - 财政年份:2003
- 资助金额:
$ 40万 - 项目类别:
TNF-alpha in cell death & neuroprotection in glaucoma
TNF-α在细胞死亡中的作用
- 批准号:
6784229 - 财政年份:2003
- 资助金额:
$ 40万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




